You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

GIP/GLP-1 dual receptor agonist

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Type 2 Diabetes, Obesity Trial in Hellerup (Semaglutide 1.34 MG/ML [Ozempic], Glucose-dependent insulinotropic polypeptide

Recruiting
  • Type 2 Diabetes
  • Obesity
  • Semaglutide 1.34 MG/ML [Ozempic]
  • +3 more
  • Hellerup, Capital Region, Denmark
    Center for Clinical Metabolic Research, Gentofte Hospital
May 19, 2022

Incidence of Retained Gastric Food on Endoscopy

Not yet recruiting
  • Gastric Content Aspiration
  • Esophagogastroduodenoscopy
  • (no location specified)
May 16, 2023

Caveolin 1 Deficiency in Response to Glucagon-like Peptide 1

Not yet recruiting
  • Overweight and Obesity
  • 24-hour ambulatory blood pressure
  • Liberal salt diet
  • (no location specified)
Oct 4, 2023

Morbid Obesity, Metabolic Syndrome, Diabetes Trial in Columbia (GLP-1 receptor agonist)

Not yet recruiting
  • Morbid Obesity
  • +4 more
  • GLP-1 receptor agonist
  • Columbia, Missouri
    University of Missouri Hospital
Nov 20, 2023

Glucagon-like Peptide-1 Receptor Agonists According to Type 2

Recruiting
  • Diabetes Mellitus, Type 2
  • GLP-1 receptor agonist
  • Bari, Italy
    Azienda Ospedaliero-Universitaria Policlinico Bari
Nov 4, 2023

Type 2 Diabetes Trial in Xuzhou (GLP-1 receptor agonist)

Recruiting
  • Type 2 Diabetes Mellitus
  • GLP-1 receptor agonist
  • Xuzhou, Jiangsu, China
    Department of Endocrinology
Apr 16, 2022

Osteoporosis, Postmenopausal, Diabetes, Type 2 Trial in Jackson (GLP-1 receptor agonist)

Recruiting
  • Osteoporosis, Postmenopausal
  • Diabetes Mellitus, Type 2
  • GLP-1 receptor agonist
  • Jackson, Mississippi
    University of Mississippi Medical Center
Aug 5, 2022

Wolfram Syndrome Trial (Tirzepatide)

Not yet recruiting
  • Wolfram Syndrome
  • (no location specified)
Dec 12, 2022

Glucagon-like Peptide 1 Receptor Agonists and Mental Health

Not yet recruiting
  • Diabetes Mellitus
  • +2 more
  • GLP-1 receptor agonist
  • (no location specified)
Aug 4, 2022

Healthy Trial in Singapore (LY3537021, Liraglutide, Placebo)

Active, not recruiting
  • Healthy
  • Singapore, Singapore
    Lilly Centre for Clinical Pharmacology
Nov 22, 2022

Ischemic Stroke Trial in Herlev (Byetta, Normosaline)

Recruiting
  • Ischemic Stroke
  • Herlev, Denmark
    Department of Neurology, Herlev-Gentofte Hospital
Nov 13, 2021

Alcohol Abuse, Alcohol Addiction, Alcohol Dependence Trial in Frederiksberg (Semaglutide Injectable Product, Placebo)

Recruiting
  • Alcohol Abuse
  • +3 more
  • Semaglutide Injectable Product
  • Placebo
  • Frederiksberg, Denmark
    Psychiatric Center Copenhagen, Frederiksberg Hospital
Jun 13, 2023

Obesity, Liver Diseases, Liver Fibrosis Trial in Boston (ESG, GLP1-RA)

Not yet recruiting
  • Obesity
  • +16 more
  • Boston, Massachusetts
    Brigham and Women's Hospital
Nov 14, 2023

Diabetes, Diabetic Kidney Disease Trial in Sha Tin (Dulaglutide, Insulin Degludec, Continuous glucose monitor)

Recruiting
  • Diabetes Mellitus
  • Diabetic Kidney Disease
  • Sha Tin, Hong Kong
    Prince of Wales Hospital
Nov 8, 2022

SEMAGLUTIDE VERSUS GLP-1 RECEPTOR AGONISTS. EFFECTIVENESS ,

Active, not recruiting
  • Weight Loss
  • +3 more
  • GLP-1 receptor agonist
  • Culleredo, A Coruña, Spain
  • +10 more
Jan 13, 2023

Type2Diabetes, ASCVD Trial (SGLT2 inhibitor, GLP-1 receptor agonist, Combination drug)

Recruiting
  • Type2Diabetes
  • ASCVD
  • SGLT2 inhibitor
  • +2 more
  • New York, New York
  • +1 more
Dec 19, 2022

Comparative Effectiveness of Empagliflozin in the US

Active, not recruiting
  • Diabetes Mellitus, Type 2
  • Boston, Massachusetts
    Bringham Women Hospital
Jan 9, 2023

Obesity, Aging Trial (Semaglutide Pen Injector)

Not yet recruiting
  • Obesity
  • Aging
  • Semaglutide Pen Injector
  • (no location specified)
May 4, 2022

Type 2 Diabetes, Obesity Trial in Sherbrooke (drug, other, diagnostic test, procedure)

Recruiting
  • Type 2 Diabetes
  • Obesity
  • Formoterol Fumarate 12 micrograms Inhalation Powder
  • +8 more
  • Sherbrooke, Quebec, Canada
    Centre de recherche du CHUS
Sep 22, 2022

Type 2 Diabetes Trial in Nanjing (Add oral hyppoglycemia drug, Add GLP-1 receptor agonist, Change insulin)

Recruiting
  • Type 2 Diabetes Mellitus
  • Add oral hyppoglycemia drug
  • +2 more
  • Nanjing, China
    Nanjing First Hospital, Nanjing Medical Univesity
Oct 11, 2022

Alcohol Dependence, in Remission, Addiction, Alcohol Trial in Copenhagen (Exenatide 2 MG Injection, BD PosiFlush (saline))

Completed
  • Alcohol Dependence, in Remission
  • Addiction, Alcohol
  • Exenatide 2 MG Injection
  • BD PosiFlush (saline)
  • Copenhagen, Frederiksberg, Denmark
    Novavì ambulatorierne
Jun 3, 2021

Type 2 Diabetes, Obesity Trial in Amsterdam (Dapagliflozin 10mg, Exenatide, exenatide)

Completed
  • Type 2 Diabetes Mellitus
  • Obesity
  • Dapagliflozin 10mg
  • +3 more
  • Amsterdam, Noord-Holland, Netherlands
    Amsterdam UMC, location VU Medical Center
Jun 8, 2021

Metabolic Disturbance, Schizophrenia, Type 2 Diabetes Trial in Copenhagen (Semaglutide, 1.34 mg/mL, Semaglutide-)

Not yet recruiting
  • Metabolic Disturbance
  • +5 more
  • Semaglutide, 1.34 mg/mL
  • Semaglutide-placebo
  • Copenhagen, Denmark
    Psychiatric Center Copenhagen, Rigshospitalet
Jun 30, 2021

Type 2 Diabetes Trial in Copenhagen (Endurance exercise training, Semaglutide)

Recruiting
  • Type 2 Diabetes
  • Copenhagen, Denmark
    Xlab, Center for Healthy Aging, Department of Biomedical Science
Feb 8, 2021

Diabetes, Type 2 Trial in San Antonio (Placebo, Exenatide, Dapagliflozin)

Active, not recruiting
  • Diabetes Mellitus, Type 2
  • Placebo
  • +3 more
  • San Antonio, Texas
    University Health System Texas Diabetic Institute
Apr 28, 2022